MiMedx to acquire Sanara MedTech in $350m regenerative medicine deal
MiMedx Group has agreed to acquire Sanara MedTech in a cash-and-stock transaction that values the Fort Worth-based surgical regenerative medicine company at approximately $350 million. The deal, announced on 29 July 2026, will see Sanara shareholders receive $33.00 in cash and 0.4735 MiMedx shares per share held, implying a total consideration of $35 per share. That represents a 46% premium to Sanara's 30-day volume-weighted average price as of 28 July.
MiMedx intends to fund the cash component through existing resources and a new $300 million term loan committed by Hayfin Capital Management. The company's existing credit facility will be repaid and terminated on close. Both boards have unanimously approved the transaction, which remains subject to Sanara shareholder approval, customary regulatory clearances, and is expected to complete before year end.
The deal
Sanara's portfolio covers collagen particulate, wound irrigation, and bone fixation for hospital surgical settings. Key branded products include CellerateRX Surgical Collagen Powder and BIASURGE Advanced Surgical Solution. The company also holds exclusive distribution rights to OsStic BioAdhesive Advanced Bone Fixation, a synthetic injectable bio-adhesive that carries an FDA Breakthrough Device designation and is targeted for commercial launch in 2027.
MiMedx chief executive Joseph Capper said the combination would "meaningfully expand our reach across several subspecialties" and accelerate growth in surgical end markets. On a combined basis, the company is guiding to 2027 total revenue "well in excess of $400 million" with an adjusted EBITDA margin above 20%, inclusive of over $20 million in anticipated run-rate cost synergies.
Sanara president and chief executive Seth Yon said the transaction "delivers a compelling and certain cash premium to shareholders while providing the opportunity to participate in the future value creation of the combined company."
Market context
The deal consolidates two companies operating in the regenerative medicine space for the operating room, a segment that has attracted sustained interest from both strategic acquirers and investors. The broader wound care and surgical biologics market sits at an intersection of ageing demographics, rising rates of chronic disease, and hospital cost-containment pressure, factors that have driven consolidation among mid-market medical technology players in recent years.
MiMedx has built its business on amniotic tissue-derived products for wound care and surgical applications, while Sanara has pursued a complementary but distinct approach centred on collagen-based and irrigation technologies. The combination extends MiMedx's product addressable market into musculoskeletal applications, where a number of larger device groups and specialist ortho-biologics companies are also active.
The OsStic bone fixation programme is the deal's most watched near-term catalyst. FDA Breakthrough Device designation can streamline the agency's review process and signals that the device addresses an unmet need, but it does not guarantee approval or accelerate the commercial timeline automatically. Investors will be watching for the 2027 launch to proceed on schedule as an early indicator of the combined portfolio's pipeline execution.
MiMedx's Marietta, Georgia base and Sanara's Texas commercial network are also seen as complementary geographies in a sector where distributor and hospital call-point relationships are a material competitive asset. The acquirer's stated aim of deepening those relationships post-close will be a key integration test alongside the delivery of the guided synergy figure.